. Author manuscript; available in PMC: 2022 Nov 14.

Published in final edited form as: Aliment Pharmacol Ther. 2021 Dec 22;55(5):593–603. doi: 10.1111/apt.16733

TABLE 3.

Cox regression analysis of time to antibodies to infliximab (ATI) development

	HR	95% CI	P value
Age <10 years	1.86	0.99–3.49	0.05
Starting dose <7.5 mg/kg	2.09	0.98–4.45	0.05
Baseline Neutrophil CD64 activity ratio >6	2.55	1.14–5.70	0.02
Week 0–14 exposure (AUC) goal, 79 348 μg h/mL	0.48	0.27–0.84	0.009
HLA DQA*105	0.75	0.38–1.50	0.43

Abbreviations: AUC, area under concentration curve; CI, confidence interval; HR, hazard ratio.